Back to search

Peptide record

TPDB92280

FAGVL Antibacterial Anticancer Antiviral Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92280
FAGVL
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF pep-lab AI4AVP dbAMP 3.0 DRAVP 2.0
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, ACP740 _ACP240, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FAVGLRAIKRALKKLRRGVRKVAKDL-NH2
Physicochemical Analysis
C134H244N46O29
NCEQHMPSTWY
RK
2963.70
12.59
10
1
13
+9
6.10
-0.154
123.85
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
4
A
5
R
0
N
1
D
0
C
0
E
0
Q
2
G
0
H
1
I
4
L
5
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 4 R: 5 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 1 L: 4 K: 5 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 3
Chemical Descriptors
26
C134H244N46O29
2963.70
12.59
+9
6.10
-0.154
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 6 records
Evidence 1 Activity

Activity

LD50
LD50 =240 µg/ml
Anticancer
240 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

LD50
LD50 =530 µg/ml
Anticancer
530 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =600 µg/ml
Anticancer
600 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =315 µg/ml
Anticancer
315 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =375 µg/ml
Anticancer
375 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 = >1000 µg/ml
Anticancer
>1000 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2